The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probably by mid-June, as reported in This is Money.
"A final decision on the harm, benefit or lack of benefit of hydroxychloroquine will be made once the evidence has been reviewed," the agency said, a day after potential safety concerns prompted it to suspend the malaria drug's use in a large trial on COVID-19 patients.
Those already in the so-called Solidarity Trial of thousands of patients who have started hydroxychloroquine can finish their treatment, the WHO said.
Newly enrolled patients will get other treatments being evaluated in the study, including Gilead Sciences' remdesivir and AbbVie's Kaletra/Aluvia.
The news source said separate hydroxychloroquine trials, including a 440-patient US study by Novartis, are continuing enrollment.
To read more NewsPoints articles, click here.